Blood pressure and heart rate in patients with ischaemic heart disease receiving nifedipine and propranolol LOUISE HARRIS, HENRY J DARGIE, PETER G LYNCH, CHRISTOPHER J BULPITT, DENNIS M KRIKLER Abstract A randomised controlled crossover trial was performed to assess the anti-anginal effects of nifedipine and propranolol separately and together. The effects of these treatments on blood pressure and heart rate were assessed at rest and after the cold pressor and mental arithmetic tests. Nifedipine and propranolol together produced the greatest reduction in supine and erect systolic and diastolic blood pressures. Propranolol (480 mg daily) lowered resting systolic/diastolic blood pressures by 7/6 mm Hg and nifedipine (60 mg daily) lowered it by 10/8 mm Hg, while in the erect position the 
mechanism linking stress and subtle alterations of lipid concentrations.
Introduction
Since the principal haemodynamic abnormality in essential hypertension is an increase in peripheral vascular resistance, there is a rationale for using drugs that lower peripheral vascular resistance by a direct action on arteriolar smooth muscle. Contraction of vascular smooth muscle depends on the influx of calcium ions across the cell membrane through the "slow channels."' Drugs which selectively block such transport, the calcium antagonists, relax vascular smooth muscle with an effect not only on peripheral vessels but also on the large extramural coronary arteries. 2 The demonstration of increased calcium transport in arteriolar smooth muscle of rats with experimental hypertension3 provides a further stimulus to investigate the role of calcium in essential hypertension and the scope for calcium antagonists in its treatment.
In a study of the anti-anginal effects of the calcium antagonist nifedipine in comparison and in combination with propranolol4 we investigated the hypotensive effect of these agents in relation to heart rate at rest and during the cold pressor and mental arithmetic tests.
Patients and methods
We recruited 18 patients (15 men, 3 women, aged 41-71 (mean 58) with chronic stable exertional angina pectoris. At the end of a twoweek run-in period on placebo all showed signs of ischaemia on exercise tests and had a resting diastolic blood pressure < 100 mm Hg after ten minutes' quiet recumbency. No patient had a history of cardiac failure or major obstructive airways disease, and none had suffered a myocardial infarct in the six months before the study.
Trial design-Four treatments were given, each for four weeksnifedipine, propranolol, the combination ofnifedipine and propranolol, and placebo. The trial was conducted double-blind and the order of administration was randomised with a Latin square balanced for order and carry-over effects. During the first two weeks of each period the agents were given at the lower doses (10 mg nifedipine and 80 mg propranolol three times a day) and during the second fortnight at the higher doses (20 mg and 160 mg three times a day respectively). The use of identical placebo tablets ensured that the treatments appeared visually identical to the patients at all times (double-dummy technique).
Assessments-Blood pressure was measured automatically with an Arteriosonde ultrasonic sphygmomanometer after 10 Statistical methods-The data obtained were subjected to an analysis of variance for a factorial experiment, such that the effects of nifedipine and propranolol could be determined alone and in combination, and any interaction between them could be estimated. 5 
Results
Supine blood pressure-The combination of nifedipine and propranolol reduced systolic and diastolic blood pressure at both low and high doses; nifedipine reduced diastolic blood pressure at the lower dose and both systolic and diastolic blood pressure at the higher dose, whereas propranolol reduced only diastolic blood pressure and only at the higher dose (table I) . While the combination of nifedipine and propranolol produced the greatest reduction in blood pressure, the joint effect was additive but not synergisticthat is, there was no positive interaction. In patients whose systolic blood pressure was 100-119 mm Hg on placebo there was little or no decrease on nifedipine, whereas those patients with systolic blood pressures of 140-180 mm Hg on placebo had the greatest response (table II) . Similarly, those patients with diastolic blood pressures of 75-84 mm Hg on placebo had little or no change on nifedipine, whereas those with pressures of 95-105 mm Hg had the greatest response.
Erect blood pressure-Systolic blood pressure was reduced by nifedipine and propranolol at the higher doses and by the combination of the two at both doses. Diastolic blood pressure was reduced by both treatments at low and high doses (table I). As with supine blood pressure, there was no positive interaction between propranolol and nifedipine when administered together.
Cold pressor test-On placebo all patients showed the usual haemodynamic response with a sharp rise in systolic blood pressure (mean 277 ±3-2 mm Hg) and a modest rise in the heart rate (mean 9 3 ±1 6 beats/min). All active treatments at high doses reduced the maximum systolic and diastolic blood pressure (table III) . Propranolol did not attenuate the maximum rise in diastolic blood pressure during the test, but the high dose of nifedipine reduced it by 6 (table IV) .
Side effects-The commonest side effect with nifedipine was mild ankle oedema (p < 0 05), while coldness of the extremities and paraesthesiae were most often seen with propranolol (table V) 
Discussion
The combination of nifedipine and propranolol produced the greatest fall in both supine and erect systolic and diastolic blood pressures, but there was no interaction between the two and their effects were additive. When administered alone nifedipine reduced supine systolic and diastolic blood pressure slightly more than did propranolol (table I). Despite the exclusion of hypertensive patients at entry, six nevertheless had resting systolic blood pressures of 140-190 mm Hg and six had resting diastolic pressures of 90-105 mm Hg during the placebo phase. The greater the blood pressure on placebo (systolic and diastolic), the greater the reduction obtained with nifedipine, whether measured in absolute units or as a percentage of the placebo value. This was not seen with propranolol or the combination (table II) . Our data showed that a sharp reduction in blood pressure is not to be expected in normotensive subjects. This is consistent with the findings in one study6 on young normotensive subjects, in whom nifedipine produced a rise in heart rate but no fall in blood pressure. Interestingly only nifedipine significantly lowered the maximum blood pressure achieved after performing mental arithmetic. Propranolol tended to have the same effect, and the differences between the drugs might have been due to a failure to use equipotent doses. Against this, the effects on standing pressure of 30 mg of nifedipine and 240 mg of propranolol were very similar, as were the effects of 60 mg nifedipine and 480 mg propranolol. When considering the maximum blood pressure after performing mental arithmetic, however, nifedipine had over twice the hypotensive effect of propranolol.
In contrast with findings in acute studies,7 nifedipine did not significantly increase the heart rate despite significantly reducing blood pressure. To examine heart rate and blood pressure responses in individual patients, the change in heart rate with nifedipine was plotted as a function of the change in systolic blood pressure (see figure) . Heart rate fell in those patients who had the greatest reductions in supine systolic blood pressure when compared with pressures on placebo. During the propranolol and combination phases, the heart rate responses in these patients were similar to those of the rest of the group.
In normal subjects8 and in patients with ischaemic heart disease9 intravenous or sublingual nifedipine appears to have no direct depressant effect on the sinus node. Indeed, in acute studies nifedipine increases the sinus rate, probably secondary to reflex sympathetic response. An electrophysiological effect is therefore unlikely to account for our findings.
Bristow et al'0 have shown reduced sensitivity of the baroreceptors in hypertensive patients with respect to controlling heart rate: hypertensive patients have a reduced ability to reduce heart rate in response to phenylephrine-induced hypertension. A similar finding was observed in patients with heart disease"; patients with heart disease also do not have the.same ability as normal people to increase heart rate when the parasympathetic system is inhibited by atropine, suggesting that parasympathetic cardiovascular regulation is abnormal in heart disease. As all of our patients had ischaemic heart disease and six had some increase in systolic blood pressure, we could not determine whether the heart rate-blood pressure responses with nifedipine reflected abnormal autonomic regulation or true physiological resetting of the baroreceptors. Supine heart rate versus supine systolic blood pressure: change from placebo to nifedipine (60 mg/day).
In our previous report4 we showed that both nifedipine and propranolol were effective in managing angina of effort but that the combination was significantly better than either drug alone. Though it has been suggested that a reduction in blood pressure in patients with coronary artery disease may precipitate angina or ischaemia by reducing myocardial blood flow, the phase which produced the greatest fall in blood pressure also produced the greatest reduction in angina. Hypertension and ischaemic heart disease often co-exist and hypertension predisposes to and possibly aggravates atherosclerotic vascular disease.'2 A regimen that lowers blood pressure and effectively improves ischaemia is thus advantageous. The combination of propranolol and nifedipine satisfies this need.
Introduction
Acute haemolysis is a rare complication of haemodialysis. There are a wide variety of medical and drug-related causes of haemolysis which may occur incidentally in patients undergoing maintenance haemodialysis. Several technical causes may also complicate haemodialysis and result in acute haemolysis. These include dialysis against hypotonic dialysis fluid, contamination of dialysis fluid by toxic concentrations of copper, zinc, chloramine, nitrate, and formaldehyde" and haemolysis due to overheated dialysate.' We report the case of a patient who developed acute haemolysis as a result of exposure to very concentrated dialysis fluid.
Case report
A 65-year-old man had started regular twice weekly haemodialysis in July 1977 because of terminal renal failure due to rapidly progressive glomerulonephritis. He started on home dialysis in May 1978 and dialysed for 10 hours twice weekly using a Meltec
